Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 20

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Effects of Dupilumab on Itch-Related Events in Atopic Dermatitis: Implications for Assessing Treatment Efficacy in Clinical Practice

Kishi, Ryoma, Toyama, Sumika, Tominaga, Mitsutoshi, Kamata, Yayoi, Komiya, Eriko, Kaneko, Takahide, Suga, Yasushi, Takamori, Kenji·2023·Cells
DOI 10.3390/cells12020239
Open this paper in CoChat — free account

Abstract

Dupilumab attenuates itch and skin inflammation in patients with atopic dermatitis (AD). However, itch-related events that are improved by dupilumab remain unclear. Therefore, the present study investigated changes in clinical scores, serum biomarkers, and the number of intraepidermal nerve fibers (IENFs) using skin biopsies and blood samples from 12 patients with moderate to severe AD before and after treatment with dupilumab. Clinical manifestations were assessed using eczema area and severity index (EASI) and visual analogue scale (VAS) scores at baseline and after 8 and 16 weeks of treatment. Serum levels of total immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), interleukin (IL)-4, IL-13, IL-22, and IL-31 were examined by electrochemiluminescence, chemiluminescent enzyme immunoassays, ProQuantum immunoassays, and enzyme-linked immunosorbent assays (ELISA) at baseline and after 8 and 16 weeks of treatment. In skin biopsies from AD patients at baseline and after 16 weeks of treatment, IENFs were examined immunohistochemically with the anti-protein gene product (PGP) 9.5 antibody. The dupilumab treatment significantly improved EASI and VAS scores and decreased serum levels of TARC, IgE, and IL-22, whereas those of IL-13 and IL-31, and the number of IENFs remained unchanged and those of IL-4 increased. VAS scores were positively correlated with serum TARC, IL-22, and IgE levels and the degree of epidermal thickening. Serum IL-31 levels were positively correlated with the number of IENFs. These results suggest that serum TARC, IL-22, and IgE levels and epidermal thickness are itch-related events associated with dupilumab treatment and that serum IL-31 levels may reflect the degree of IENF density in AD patients. Therefore, dynamic changes may be used to assess the efficacy of dupilumab treatment to treat itching and inflammation in patients with AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells12020239

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 33

  1. Saeki, 2022, English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021, J. Dermatol., 49, e315
  2. Barbarot, 2018, Epidemiology of atopic dermatitis in adults: Results from an international survey, Allergy, 73, 1284, 10.1111/all.13401 · DOI · Paper page
  3. Simpson, 2016, Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults, J. Am. Acad. Dermatol., 74, 491, 10.1016/j.jaad.2015.10.043 · DOI · Paper page
  4. Moniaga, C.S., Tominaga, M., and Takamori, K. (2021). The Pathology of Type 2 Inflammation-Associated Itch in Atopic Dermatitis. Diagnostics, 11. · DOI · Paper page
  5. Roekevisch, 2014, Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systemic review, J. Allergy Clin. Immunol., 133, 429, 10.1016/j.jaci.2013.07.049 · DOI · Paper page
  6. Gooderham, 2017, Review of systemic treatment options for adult atopic dermatitis, J. Cutan. Med. Surg., 21, 31, 10.1177/1203475416670364 · DOI
  7. Toyama, S., Tominaga, M., and Takamori, K. (2022). Treatment options for troublesome itch. Pharmaceuticals, 15. · DOI
  8. Allinne, 2020, Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation, Allergy, 75, 1188, 10.1111/all.14151 · DOI · Paper page
  9. Blauvelt, 2017, Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial, Lancet, 389, 2287, 10.1016/S0140-6736(17)31191-1 · DOI · Paper page
  10. Kakinuma, 2001, Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity, J. Allergy Clin. Immunol., 107, 535, 10.1067/mai.2001.113237 · DOI · Paper page
  11. Shaheen, 2011, Study of the role of serum folic acid in atopic dermatitis: A correlation with serum IgE and disease severity, Indian J. Dermatol., 56, 673, 10.4103/0019-5154.91827 · DOI
  12. Dhar, 2005, Correlation of the severity of atopic dermatitis with absolute eosinophil counts in peripheral blood and serum IgE levels, Indian J. Dermatol. Venereol. Leprol., 71, 246, 10.4103/0378-6323.16615 · doi:10.4103/0378-6323.16615
  13. Yamauchi, 2021, Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis, Int. J. Dermatol., 60, 190, 10.1111/ijd.15183 · DOI
  14. Schaft, 2020, Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry, Allergy, 75, 116, 10.1111/all.14080 · DOI
  15. Tominaga, 2014, Itch and nerve fibers with special reference to atopic dermatitis: Therapeutic implications, J. Dermatol., 41, 205, 10.1111/1346-8138.12317 · DOI · Paper page
  16. Toyama, S., Tominaga, M., and Takamori, K. (2021). Connections between immune-derived mediators and sensory nerves for itch sensation. Int. J. Mol. Sci., 22. · DOI
  17. Hanifin, 1980, Diagnostic features of atopic dermatitis, Acta Derm Venereol., 92, 44, 10.2340/00015555924447 · DOI · Paper page
  18. Leshem, 2015, What the eczema area and severity index score tells us about the severity of atopic dermatitis: An interpretability study, Br. J. Dermatol., 172, 1353, 10.1111/bjd.13662 · DOI · Paper page
  19. Phan, 2012, Assessment of pruritus intensity: Prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus, Acta Derm. Venereol., 92, 502, 10.2340/00015555-1246 · DOI · Paper page
  20. Faiz, 2019, Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort, J. Am. Acad. Dermatol., 81, 143, 10.1016/j.jaad.2019.02.053 · DOI · Paper page
  21. Castro, 2018, Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma, N. Engl. J. Med., 378, 2486, 10.1056/NEJMoa1804092 · DOI · Paper page
  22. Kim, 2013, TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation, Sci. Transl. Med., 5, 170ra16, 10.1126/scitranslmed.3005374 · DOI · Paper page
  23. Imai, 2013, Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice, Proc. Natl. Acad. Sci. USA, 110, 13291, 10.1073/pnas.1307321110 · DOI · Paper page
  24. Worm, 2020, Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: A randomized clinical trial, JAMA Dermatol., 156, 131, 10.1001/jamadermatol.2019.3617 · DOI · Paper page
  25. Fukuyama, 2017, Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib, Eur. J. Pharmacol., 794, 20, 10.1016/j.ejphar.2016.11.020 · doi:10.1016/j.ejphar.2016.11.020
  26. Cevikbas, 2020, Physiology and pathophysiology of itch, Physiol. Rev., 100, 945, 10.1152/physrev.00017.2019 · DOI · Paper page
  27. Tseng, 2021, OncostatinM can sensitize sensory neurons in inflammatory pruritus, Sci. Transl. Med., 13, e3037, 10.1126/scitranslmed.abe3037 · DOI
  28. Feld, 2016, The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves, J. Allergy Clin. Immunol., 138, 500, 10.1016/j.jaci.2016.02.020 · DOI · Paper page
  29. Takemura, M., Nakahara, T., Hashimoto-Hachiya, A., Furue, M., and Tsuji, G. (2018). Glyteer, soybean tar, impairs IL-4/Stat6 signaling in murine bone marrow-derived dendritic cells: The basis of its therapeutic effect on atopic dermatitis. Int. J. Mol. Sci., 19. · DOI
  30. Souwer, 2010, IL-17 and IL-22 in atopic allergic disease, Curr. Opin. Immunol., 22, 821, 10.1016/j.coi.2010.10.013 · DOI
  31. Boniface, 2005, IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes, J. Immunol., 174, 3695, 10.4049/jimmunol.174.6.3695 · DOI · Paper page
  32. Bissonnette, 2019, Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis, J. Allergy Clin. Immunol., 143, 155, 10.1016/j.jaci.2018.08.022 · DOI · Paper page
  33. Hayashida, 2011, Significant correlation of serum IL-22 levels with CCL17 levels in atopic dermatitis, J. Dermatol. Sci., 61, 78, 10.1016/j.jdermsci.2010.08.013 · DOI

Cited by

See all 20

Metadata

Authors
Kishi, R., Toyama, S., Tominaga, M., Kamata, Y., Komiya, E., Kaneko, T., Suga, Y., & Takamori, K.
Venue
Cells
Publisher
MDPI AG
Published
2023-01-05
Volume
12
Issue
2
Pages
239
ISSN
2073-4409
DOI
10.3390/cells12020239
Cited by
20
References
6
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • Grant-in-Aid for Scientific Research (B) (20H03568, 22H02956, 19K17817, 21K16307)
  • Grant-in-Aid for Early-Career Scientists (20H03568, 22H02956, 19K17817, 21K16307)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Dupilumab on Itch-Related Events in Atopic Dermatitis: Implications for Assessing Treatment Efficacy in Clinical Practice. https://app.cochat.ai/papers/10.3390/cells12020239
The paper
Kishi, R., Toyama, S., Tominaga, M., Kamata, Y., Komiya, E., Kaneko, T., Suga, Y., & Takamori, K. (2023). Effects of Dupilumab on Itch-Related Events in Atopic Dermatitis: Implications for Assessing Treatment Efficacy in Clinical Practice. Cells. https://doi.org/10.3390/cells12020239

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.